• 2 months 3 weeks ago Help us improve our website: http://t.co/vY9vRzmYRH! Please take our visitor survey: http://t.co/8gY0wRZtGx. Thank you...
  • 2 months 3 weeks ago 1st European Research Forum on Healthy Ageing: 03 Sept in Bxl. Policy makers, scientists, industrials: save the date! http://t.co/6TXrBI5rdt
  • 3 months 4 days ago Gender inequalities in health: a matter of policies according to @sophieproject http://t.co/TzwZzXko3g
  • 4 months 1 day ago 1/3 of cancer patients killed by 'fat-burning' process termed cachexia, @CNIO_Cancer researchers say http://t.co/GjfipsdG2R
  • 4 months 4 weeks ago New EU research project @pneumonp aims to tackle antibiotic resistance via inhalable nano therapeutics #nanomedicine http://t.co/VQN9WHojG2
  • 5 months 2 weeks ago Urban renewal improves the health of neighbours in Barcelona according to EU-funded project @sophieproject http://t.co/F0mKCdPBZ5
  • 5 months 2 weeks ago Check this article on #CommHERE: how to spread the word about research and reach out beyond the scientific community http://t.co/VDcKVDEfcc
  • 6 months 2 weeks ago Scientists @CNIO_Cancer among the 40 most important global researchers http://t.co/Rc0hIsq6dN
  • 6 months 3 weeks ago 2nd workshop @CIBER_ISCIII to strengthen the EU‐LAC Health Research Cooperation http://t.co/93qLQObcQj
  • 8 months 2 weeks ago The European Symposium in Drug Synthesis @unisiena will take place on May 18-23. You can register until April 15!! http://t.co/V8kxQIev9S

HEPAVAC

Portrait of Professor Luigi Buonaguro, Coordinator of the European health research project HEPAVAC

Prof. Luigi Buonaguro

Scientific coordinator of HEPAVAC, based at Istituto Nazionale Tumori 'Fondazione Pascale' of Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy

Research field

Cancer Immunotherapy

If you like this
If you want to know more
Research Profile

Who?

“I've always been fascinated by the ability of preventive vaccines to halt human diseases. Vaccines can also be used to treat diseases, but this is not very effective yet. My goal is to give patients with devastating diseases such as liver cancer hope by improving the efficacy of therapeutic vaccines”, says Luigi Buonaguro.

Why?

Hepatocellular carcinoma is very common in both women and men. The prognosis is poor: only 5-6% of patients survive more than 5 years after diagnosis. Novel therapies are urgently required. Cancer vaccines – also called immunotherapeutic interventions- could represent an important turning point in HCC therapy.

What?

The HEPAVAC project aims to develop a therapeutic vaccine for hepatocellular carcinoma (HCC), a common form of liver cancer. The clinical trial will include a personalised approach, taking into account genetic differences between patients. The ultimate aim is to increase life expectancy of early-stage HCC patients.

How?

HEPAVAC will determine the feasibility, safety and biological efficacy of the HCC vaccine in a clinical trial involving six European countries. The project has enabled a close collaboration between scientists and physicians from disciplines such as genomics, peptidomics, bioinformatics, systems biology and immunomonitoring.

It all depends on the liver

In the Picture
In the Picture
HEPAVAC project website American cancer society: what is liver cancer? National Cancer Institute of NIH: liver cancer Liver Cancer Incidence and Mortality Worldwide In Focus article 'Vaccines of the Third Kind' Cancer Vaccine Development for Hepatocellular Carcinoma flyer PDF versionPDF version
Image credits

Background image: HEPAVAC

Portrait of the project coordinator: HEPAVAC

Timeline (in chronological order): 1891: Hospital for Special Surgery Archives; 1909: Hata Memorial Museum, Shimane; 2003: Wikimedia commons; 2008: Microsoft images